China SXT Pharmaceuticals, Inc.: net intangible assets excluding goodwill

What this measure means

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

Exact concept: us-gaap:IntangibleAssetsNetExcludingGoodwill. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2023-03-31 to 2026-03-31. The SEC response was captured on 2026-09-21.

Selected filing history

Related financial histories

• China SXT Pharmaceuticals, Inc.: total assets
• China SXT Pharmaceuticals, Inc.: total liabilities
• China SXT Pharmaceuticals, Inc.: stockholders equity
• China SXT Pharmaceuticals, Inc.: cash and cash equivalents
• China SXT Pharmaceuticals, Inc.: net income or loss
• China SXT Pharmaceuticals, Inc.: operating cash flow
• China SXT Pharmaceuticals, Inc.: capital expenditure payments
• China SXT Pharmaceuticals, Inc.: revenue
• China SXT Pharmaceuticals, Inc.: financing cash flow
• China SXT Pharmaceuticals, Inc.: investing cash flow
• China SXT Pharmaceuticals, Inc.: retained earnings or deficit
• China SXT Pharmaceuticals, Inc.: basic weighted-average shares
• China SXT Pharmaceuticals, Inc.: diluted weighted-average shares
• China SXT Pharmaceuticals, Inc.: basic earnings per share
• China SXT Pharmaceuticals, Inc.: diluted earnings per share
• China SXT Pharmaceuticals, Inc.: income tax expense or benefit
• China SXT Pharmaceuticals, Inc.: net property, plant and equipment
• China SXT Pharmaceuticals, Inc.: share-based compensation expense
• China SXT Pharmaceuticals, Inc.: operating income or loss
• China SXT Pharmaceuticals, Inc.: current assets
• China SXT Pharmaceuticals, Inc.: interest expense
• China SXT Pharmaceuticals, Inc.: current liabilities
• China SXT Pharmaceuticals, Inc.: current accounts payable
• China SXT Pharmaceuticals, Inc.: net finite-lived intangible assets
• China SXT Pharmaceuticals, Inc.: net current accounts receivable
• China SXT Pharmaceuticals, Inc.: operating expenses
• China SXT Pharmaceuticals, Inc.: net inventory
• China SXT Pharmaceuticals, Inc.: gross profit
• China SXT Pharmaceuticals, Inc.: cost of revenue
• China SXT Pharmaceuticals, Inc.: research and development expense
• China SXT Pharmaceuticals, Inc.: common shares outstanding
• China SXT Pharmaceuticals, Inc.: cash including restricted cash
• China SXT Pharmaceuticals, Inc.: additional paid-in capital
• China SXT Pharmaceuticals, Inc.: accumulated other comprehensive income or loss
• China SXT Pharmaceuticals, Inc.: operating lease right-of-use asset
• China SXT Pharmaceuticals, Inc.: operating lease liability
• China SXT Pharmaceuticals, Inc.: long-term debt
• China SXT Pharmaceuticals, Inc.: gross property, plant and equipment
• China SXT Pharmaceuticals, Inc.: accumulated depreciation on property, plant and equipment
• China SXT Pharmaceuticals, Inc.: prepaid expenses and other current assets
• China SXT Pharmaceuticals, Inc.: current contract liabilities
• China SXT Pharmaceuticals, Inc.: pre-tax income or loss from continuing operations
• China SXT Pharmaceuticals, Inc.: profit or loss including noncontrolling interests
• China SXT Pharmaceuticals, Inc.: comprehensive income or loss
• China SXT Pharmaceuticals, Inc.: general and administrative expense
• China SXT Pharmaceuticals, Inc.: depreciation expense
• China SXT Pharmaceuticals, Inc.: depreciation, depletion and amortization
• China SXT Pharmaceuticals, Inc.: amortization of intangible assets
• China SXT Pharmaceuticals, Inc.: nonoperating interest expense
• China SXT Pharmaceuticals, Inc.: other nonoperating income or expense
• China SXT Pharmaceuticals, Inc.: nonoperating income or expense
• China SXT Pharmaceuticals, Inc.: deferred income tax expense or benefit
• China SXT Pharmaceuticals, Inc.: interest paid, net
• China SXT Pharmaceuticals, Inc.: income taxes paid, net
• China SXT Pharmaceuticals, Inc.: change in accounts receivable
• China SXT Pharmaceuticals, Inc.: change in inventories
• China SXT Pharmaceuticals, Inc.: change in accounts payable

Inspect the source

Entity

China SXT Pharmaceuticals, Inc. / CIK 0001723980

Captured

2026-09-21T17:27:28.025Z

SEC response SHA-256

5d9b67895a776113ebb838d9f4e37ed9332236cdc6d97b3ceb041843d0247442

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001723980.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))